Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:LEGN News 8 December 2025 - 7 January 2026

Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

New York, January 7, 2026, 12:32 (EST) — Regular session Shares of Legend Biotech Corp rose 7.4% to $22.53 in midday trading on Wednesday after Oppenheimer initiated coverage with an “Outperform” rating and set a $75 price target, according to MarketBeat. StreetInsider said Oppenheimer analyst Trevor Allred authored the initiation note. MarketBeat Why it matters now: Legend’s stock has been under pressure and touched a 52-week low of $21.16 earlier this week, keeping investors sensitive to any shift in the narrative around its lead product, Carvykti. Carvykti is a CAR‑T therapy — a personalized cancer treatment that uses a patient’s
7 January 2026
·
Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

New York, January 5, 2026, 15:53 EST — Regular session Legend Biotech Corp (LEGN) shares fell 4.7% to $20.49 on Monday, after touching $20.29 — a fresh 52-week low — in afternoon trading. The stock is about 55% below its 52-week high of $45.30. SoFi Money rotated into energy and bank stocks on Monday, lifting Wall Street’s main indexes, after a U.S. military strike captured Venezuelan President Nicolas Maduro. “Energy stocks are really benefiting from the expectation that President Trump is intending to send them in,” said Rob Haworth, senior investment strategist at U.S. Bank Wealth Management. Data showed U.S.
5 January 2026
·
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

U.S. stocks are trading in a holding pattern on Wednesday, December 10, 2025, as Wall Street waits for the Federal Reserve’s final interest‑rate decision of the year. Index moves are modest, but beneath the surface a cluster of mid‑cap names is posting double‑digit percentage declines, led by Dyne Therapeutics (DYN), SLM Corp (SLM), Kontoor Brands (KTB) and Waystar Holding (WAY). Investing.com+1 According to real‑time data from StockScan, the 10 biggest U.S. stock losers today by percentage move (among actively traded listed shares) are: StockScan Below is a breakdown of what’s driving today’s biggest losers, plus how they fit into the
10 December 2025
···········
Legend Biotech (LEGN) Stock Hits New Lows: Oversold CAR-T Leader or Long-Term Opportunity?

Legend Biotech (LEGN) Stock Hits New Lows: Oversold CAR-T Leader or Long-Term Opportunity?

As of December 9, 2025, shares of Legend Biotech Corporation (NASDAQ: LEGN) are under heavy pressure even as the company posts strong growth from its flagship CAR-T therapy, CARVYKTI. Here’s a deep dive into the latest news, forecasts, analyst calls and technical signals that are driving sentiment around Legend Biotech stock today. Where Legend Biotech Stock Trades Now Legend Biotech’s American Depositary Shares (ADS) were recently trading around $24.1, down roughly 8% on the day and hovering near fresh 52-week lows. Benzinga On December 9, 2025, the stock: A company news brief from Investing.com highlighted that Legend Biotech shares hit
9 December 2025
·
Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech Corp. (NASDAQ: LEGN) shares are under heavy pressure on December 8, 2025, trading in the mid‑$20s and touching a new 52‑week low around $25.66 during the session. The slide comes despite strong clinical momentum for its flagship CAR‑T therapy CARVYKTI® and robust revenue growth, as investors react to valuation resets and ongoing concerns about profitability and cash flow. Investing.com+1 This article rounds up the key news and analysis on Legend Biotech stock from December 8, 2025 and the days immediately preceding it, and looks at what Wall Street expects next for LEGN. Disclaimer: This article is for information
8 December 2025
··
Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Wall Street kicked off “Fed week” in a cautious mood on Monday, December 8, 2025. U.S. stock futures ticked slightly higher, with the S&P 500 hovering just below record territory as traders priced in an ~85–90% chance of another 25‑basis‑point rate cut at the Federal Reserve’s final meeting of the year. TechStock²+1 Beneath that calm index-level picture, several individual U.S. stocks logged outsized losses, led by biotech, AI‑chip, consumer staples and med‑tech names. According to TipRanks’ “Stock Market Losers Today” screen for U.S. equities (data from late morning Eastern time), the day’s biggest percentage decliners included: TipRanks Below is a closer look at the key stories, forecasts and analyst commentary behind the
8 December 2025
············

Stock Market Today

AT&T stock price: T slips after $6.5B bond sale as payrolls, CPI loom next week

AT&T stock price: T slips after $6.5B bond sale as payrolls, CPI loom next week

7 February 2026
AT&T shares closed down 0.7% at $27.13 on Friday, underperforming the S&P 500’s 1.97% gain. The company completed a $6.5 billion global notes sale this week, with maturities from 2031 to 2056 and coupons between 4.4% and 6%. Investors await delayed U.S. jobs and inflation data, along with T-Mobile’s upcoming earnings update.
GE Vernova stock price jumps toward $800 — what to know before Monday trade

GE Vernova stock price jumps toward $800 — what to know before Monday trade

7 February 2026
GE Vernova shares jumped 5.7% to $779.35 Friday after Baird upgraded the stock and the Dow closed above 50,000. The company’s onshore wind unit reported 1.1 GW in U.S. repower orders for 2025, a figure previously disclosed. GE Vernova also completed a $2.6 billion senior notes offering to help fund its Prolec GE stake purchase. Next earnings report is set for April 22.
Go toTop